Jennifer Cultrera is an Oncology physician. OpenAlex indexes 70 publications with 1,752 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 N Us Highway 441
Suite 540
Lady Lake, FL 321598975
Telephone
352-753-9777Provider last certified this registry record 24 Mar 2026.
Clinical trials
- Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Sponsor: Traws Pharma, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
71 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20259 payments
- Gilead Sciences, Inc.Program year20256 payments
- ABBVIE INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
31.7%Parenteral Iron Replacement16%Iron sucrose100%Part B, office-administered≥28 patientsErythropoiesis-stimulating Agent8.1%Epoetin alfa100%Part B, office-administered≥33 patients+ 3 more classes in this area
Metabolism & gastrointestinal
20%Substance P/Neurokinin-1 Receptor Antagonist11.7%Aprepitant100%Part B, office-administered≥19 patientsOther antiemetics5.2%Fosaprepitant100%Part B, office-administered≥12 patients+ 6 more classes in this area
Cancer & immunology
17.7%PD-1 inhibitor13.4%Pembrolizumab100%Part B, office-administered≥13 patientsTNF inhibitor3.1%Infliximab100%Part B, office-administered≥12 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”